

# Thailand's One Health Report

## on Antimicrobial Consumption and Antimicrobial Resistance

# in 2020



### Data on monitoring and evaluation of the Goals of Thailand's National Strategic Plan on Antimicrobial Resistance 2017-2021


Indicator	Data			
	2017	2018	2019	2020
<b>A. Antimicrobial consumption in humans and animals*</b>				
Antimicrobial consumption in humans (Defined Daily Doses/1,000 inhabitants/day, DID)	54.6 (baseline)	50.5 (↓7.5%)	51.6 (↓5.6%)	46.3* (↓15.2%)
Antimicrobial consumption in food-producing animals (mg/PCU <sub>Thailand</sub> )	658.7 (baseline)	522.0 (↓20.8%)	336.3 (↓49.0%)	421.5* (↓36.0%)
<b>B. AMR in humans and animals</b>				
<b>Percentage of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA)</b>				
- AMR in humans, lab-based surveillance (NARST)	9.6	8.1	9.4	6.5
- AMR in patients with hospital-associated Infections	-	33.8	36.0	29.44
<b>Percentage of <i>Escherichia coli</i> resistant to 3<sup>rd</sup>-generation cephalosporin</b>				
- AMR in humans, lab-based surveillance (NARST)	44.0	42.7	43.9	41.4
- AMR in patients with hospital-associated Infections	-	69.4	54.4	71.8
- AMR in chicken caeca**	1.7	1.8	1.0	1.8
- AMR in pig caeca**	9.6	11.1	8.9	13.6
<b>Percentage of carbapenem-resistant <i>Acinetobacter baumannii</i> (CRAB)</b>				
- AMR in humans, lab-based surveillance (NARST)	69.8	68.2	69.7	71.6
- AMR in patients with hospital-associated Infections	-	89.8	74.6	87.8
<b>Percentage of carbapenem-resistant <i>Enterobacteriaceae</i> (CRE)</b>				
- AMR in humans, lab-based surveillance (NARST)				
◦ <i>Escherichia coli</i>	2.4	2.8	3.3	3.4
◦ <i>Klebsiella pneumoniae</i>	10.1	12.3	12.5	12.6
- AMR in patients with hospital-associated Infections				
◦ <i>Escherichia coli</i>	-	12.2	21.0	27.0
◦ <i>Klebsiella pneumoniae</i>		36.8	33.0	44.7
<b>C. Public knowledge on AMR (percent)</b>	23.7 (baseline)	-	24.3 (↑0.6 percentage point)	-

\*Data are under peer review by Working Group on verification of antimicrobial consumption data.

\*\*cefotaxime

## I. Antimicrobial Consumption in Humans<sup>1</sup>

Human antimicrobial consumption (Defined Daily Doses, DDDs) and population in Thailand (including migrants) (Millions)




J01, antibacterials for systemic use; A07AA, antibiotics for alimentary tract; P01AB, nitroimidazole derivatives; J02, antimycotics for systemic use; D01BA, antifungals for systemic use; J04A, drugs for treatment of tuberculosis; P01B, antimalarials; J05, antivirals for systemic use

### Top 10 antimicrobials for humans in 2020 and their consumption from 2017-2020 (DDD/1,000 inhabitants/day, DID)

Rank in 2020	Antimicrobial agent	Consumption (DDD/1,000 inhabitants/day)			
		2020	2019	2018	2017
1	Amoxicillin	6.6	9.2	9.3	10.1
2	Emtricitabine, tenofovir disoproxil and efavirenz	2.8	2.5	1.8	1.3
3	Lamivudine	2.5	1.8	2.5	2.6
4	Tetracycline	2.4	2.3	3.7	3.4
5	Amoxicillin with beta-lactamase inhibitor	2.3	2.3	2.6	5.1
6	Ampicillin	2.2	2.2	2.2	1.4
7	Ketoconazole	2.0	2.4	2.1	3.7
8	Tenofovir disoproxil	1.6	1.6	0.2	0.1
9	Norfloxacin	1.6	1.4	1.4	2.0
10	Doxycycline	1.6	2.0	2.2	2.4


### Human Antimicrobial Consumption Classified by WHO Critically Important Antimicrobials (DDD/1,000 inhabitants/day, DID)



<sup>1</sup> Data source: Thailand Surveillance of Antimicrobial Consumption

## II. Antimicrobial Consumption in Food-Producing Animals<sup>2</sup>


Antimicrobial consumption in food-producing animals (tonnes of active pharmaceutical ingredient, API) and food-producing animal population (1,000 tonnes of PCU<sub>Thailand</sub>)



Top 10 antimicrobials for food-producing animals in 2020 and their consumption in 2017 and 2018 and 2019 (mg/PCU<sub>Thailand</sub>)

Rank in 2020	Antimicrobial agent	Consumption (mg/PCU <sub>Thailand</sub> )			
		2020	2019	2018	2017
1	Amoxicillin	139.8	125.1	210.4	11.4
2	Chlortetracycline	57.1	44.8	42.8	52.9
3	Tiamulin	45.6	36.2	60.2	7.7
4	Bacitracin	45.6	18.4	14.6	10.5
5	Colistin	26.2	18.6	23.5	0.4
6	Tilmicosin	25.6	16.3	16.7	8.9
7	Halquinol	22.2	14.8	80.5	73.3
8	Doxycycline	14.5	13.0	14.6	19.1
9	Tylosin	8.2	8.8	14.3	223.7
10	Neomycin	5.5	6.0	7.8	5.9


Antimicrobial consumption in food-producing animals classified by WHO Critically Important Antimicrobials (mg/PCU<sub>Thailand</sub>)



<sup>2</sup> Data source: Thailand Surveillance of Antimicrobial Consumption

### III. Antibacterial Consumption in Food-Producing Animals (Medicated Feed Produced by Feed mills)<sup>3</sup>

Antibacterial consumption in medicated feed by species of food-producing animals in 2019 (tonnes of active pharmaceutical ingredient, API)




QA07, antimicrobial agents for intestinal use; QJ01, antimicrobial agents for systemic use

#### Top 10 antibacterials used in medicated feed for pigs and poultry in 2020 (tonnes of API)

Rank	Pigs		Poultry	
	Antibacterial	Tonnes of API	Antibacterial	Tonnes of API
1	Amoxicillin	343.5	Bacitracin	13.2
2	Tiamulin	227.6	Tilmicosin	1.2
3	Halquinol	204.6	Tylvalosin	0.8
4	Chlortetracycline	84.7	Tiamulin	0.6
5	Tilmicosin	83.0	Amoxicillin	0.4
6	Colistin	50.4	Doxycycline	<0.1
7	Doxycycline	21.8	Halquinol	<0.1
8	Lincomycin	18.9	Kitasamycin	<0.1
9	Bacitracin	14.3	Chlortetracycline	<0.1
10	Tylvalosin	4.9	Colistin	<0.1

#### Antibacterial consumption in medicated feed for pigs and poultry by WHO Critically Important Antimicrobials and chemical class in 2019 (tonnes of API)




<sup>3</sup> Data source: Thailand Surveillance of Antimicrobial Consumption


<sup>4</sup> Antimicrobials with less than 0.1 tonnes of API for both pigs and poultry (non-CIA penicillins, phosphoglycolipids and aminocyclitols) are not shown.

#### IV. Antimicrobial Resistance in Humans<sup>5</sup>


Percentage of Methicillin-resistant *Staphylococcus aureus* (MRSA) in 2017-2020




Percentage of *Escherichia coli* with 3<sup>rd</sup>-generation cephalosporin resistance in 2017-2020



Percentage of Carbapenem-resistant *Acinetobacter baumannii* (CRAB) in 2017-2020



Percentage of Carbapenem-resistant *Enterobacteriaceae* (CRE) in 2017-2020




Note: Carbapenem-resistant *Enterobacteriaceae* (CRE) included *Klebsiella pneumoniae* and *Escherichia coli*.


<sup>5</sup> Data source: National Antimicrobial Resistance Surveillance Center Thailand (NARST), National Institute of Health, Department of Medical Sciences, and Department of Disease Control

## V. Antimicrobial Resistance in Patients with Hospital-Associated Infections<sup>6</sup>

Percentage of Carbapenem-resistant *Acinetobacter baumannii* (CRAB) in patients with hospital-associated infections in 2018-2020




Percentage of Carbapenem-resistant *Enterobacteriaceae* (CRE) in patients with hospital-associated infections in 2018-2020




Note: Carbapenem-Resistant *Enterobacteriaceae* (CRE) included *Klebsiella pneumoniae* and *Escherichia coli*.

Percentage of *Escherichia coli* with 3<sup>rd</sup>-generation cephalosporin resistance in patients with hospital-associated infections in 2018-2020



Percentage of Methicillin-resistant *Staphylococcus aureus* (MRSA) in patients with hospital-associated infections in 2018-2020




<sup>6</sup> Data source: Surveillance of Hospital-associated Infection, Bamrasnaradura Infectious Disease Institute


## VI. Antimicrobial Resistance in Food-Producing Animals<sup>7</sup>

### *Escherichia coli*

Percentage of antimicrobial resistance of *Escherichia coli* (2017-2020)



Note: Number of isolates differs between source and years




Note: Number of isolates differs between source and years


<sup>7</sup> Data source: Department of Livestock Development

## Salmonella spp.

Percentage of antimicrobial resistance of *Salmonella* spp. (2017-2020)



Note: Number of isolates differs between source and years




Note: Number of isolates differs between source and years



### Enterococcus spp.


Percentage of antimicrobial resistance of *Enterococcus* spp. (2017-2020)



Note: Number of isolates differs between years

### Campylobacter spp.

Percentage of antimicrobial resistance of *Campylobacter* spp. (2017-2020)



Note: Number of isolates differs between years

Note

Dotted lines for note-taking.

# Note

A series of horizontal dotted lines for writing notes.



**Produced by:**  
Health Policy and Systems Research on Antimicrobial Resistance (HPSR-AMR) Network

**Published by:**  
International Health Policy Program, Ministry of Public Health

**Address:**  
Ministry of Public Health, Tiwanon Rd. Nonthaburi 11000, Thailand  
Phone: +66 (0) 2590-2366- 7 Fax: +66 (0) 2590-2385